Ratings Recce Pharmaceuticals Ltd

Equities

RCE

AU000000RCE5

Delayed Australian S.E. Other stock markets 01:24:48 13/05/2024 BST			5-day change	1st Jan Change
0.65 ^AUD	+1.56%		-1.52%	+21.50%

05-10	Recce Pharmaceuticals Finds 'Promising' Results From Nebulized RECCE 327 Pilot Study	MT
05-08	Recce Pharmaceuticals Ltd Receives New Patent in China for RECCE Anti-Infectives from China National Intellectual Property Administration	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
Low profitability weakens the company.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's "enterprise value to sales" ratio is among the highest in the world.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
RECCE PHARMACEUTICALS LTD	+21.50%	86.19M	-
ELI LILLY AND COMPANY	+30.38%	684B	C+
NOVO NORDISK A/S	+26.51%	568B	B
JOHNSON & JOHNSON	-4.36%	361B	C+
MERCK & CO., INC.	+19.30%	329B	B-
ABBVIE INC.	+3.73%	284B	C+
ASTRAZENECA PLC	+16.70%	240B	B+
NOVARTIS AG	+8.78%	208B	B-
ROCHE HOLDING AG	-7.93%	200B	A+
AMGEN INC.	+7.68%	166B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes